{"id":"W3155089045","doi":"10.1016/s1470-2045(21)00098-x","title":"Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; AstraZeneca","keywords":"Medicine; BRCA mutation; Internal medicine; Ovarian cancer; Clinical endpoint; Oncology; Olaparib; Placebo; Quality of life (healthcare); Cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Clinical trial; Progressive disease; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002107515,0.001956789,0.003133484,0.0003545896,0.0004377849,0.001240417,0.001008645,0.002193493,0.00471725],"category_scores_gemma":[0.002544409,0.0006729304,0.004127703,0.0005101633,0.001330473,0.001264351,0.0007068406,0.003987075,0.0005649081],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001128314,"about_ca_system_score_gemma":0.0009238216,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001635528,"about_ca_topic_score_gemma":0.002350151,"domain_scores_codex":[0.9988942,0.0006026474,0.00006229352,0.0002288998,0.00006729769,0.0001447811],"domain_scores_gemma":[0.9978189,0.0007243052,0.0006335407,0.0001713222,0.00008210432,0.0005698392],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.986937,0.001993325,0.00225551,0.0002588737,0.001396385,0.00001865297,0.00004376554,0.0002968094,0.0005129747,0.00004242374,0.0002304276,0.006013758],"study_design_scores_gemma":[0.8962571,0.08562639,0.01494534,0.0000489042,0.001594008,0.00003976471,0.00004789035,0.0005584788,0.0002348409,0.0002292259,0.0003801117,0.0000380092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948969,0.002407919,0.0001688237,0.0003230935,0.0001899362,0.0005306845,0.0008156418,0.00002420672,0.0006427097],"genre_scores_gemma":[0.9949813,0.0009555386,0.0004217831,0.0004457572,0.0002875715,0.00092499,0.001062408,0.00000854211,0.0009121735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00471725,"threshold_uncertainty_score":0.01578081,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02288432002918147,"score_gpt":0.3707904252599238,"score_spread":0.3479061052307423,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}